The study evaluated the addition of Gemzar to the current standard-of-care of epirubicin and cyclophosphamide followed by Taxol (paclitaxel) in patients with stage II-III breast cancer. The treatment
The therapy, currently called TG 4001 / R3484 (MVA-HPV-IL2), has been developed for the treatment of high grade cervical intraepithelial neoplasia, which is the abnormal growth of cells
The phase II trial enrolled 217 women, randomized into three treatment groups receiving MF101 (5 grams/day), MF101 (10 grams/day), or placebo for twelve weeks. Bionovo’s primary objectives in
California-based BioGenex is licensed to utilize Ventana patented methods of bar-coding slides and reagents to control automated processing of samples, and Ventana is licensed to use BioGenex’s patented
The interim results from the phase II trial showed that the response rate and survival are comparable to currently approved second-line therapies for non-small cell lung cancer (NSCLC),
The study, which included 649 patients worldwide, was originally designed to measure an improvement in overall survival. However, in prior consultation with the FDA and European regulatory authorities,
The injectable form of the drug, ZIO-101, is currently in three phase II studies including advanced myeloma, liver cancer, and hematological malignancies. The phase I study of oral
The trial was designed to assess the safety and tolerability of bavituximab in combination with common chemotherapy agents in advanced cancer patients with metastatic disease who had failed
The patients must have failed to respond to injectable interferon, or relapsed after initially responding to injectable interferon, and will receive one of three different dosages of oral
The FDA requested additional clinical data for the licensure of Provenge, the company’s prostate cancer vaccine, after Dendreon submitted its marketing authorization application. Dendreon cut 40 marketing jobs
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.